Press releases

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS) has, in accordance with the intention announced by the Company through a press release, on December 12, 2025, resolved on a directed issue of a total of 2,055,330 shares (the “Directed Issue”). A number of Nordic, international, institutional and professional investors participated in the Directed Issue, including both new and existing shareholders. Through the Directed Issue, Curasight receives DKK 16.4 million before transaction costs. The Directed Issue has been carried out pursuant to the authorization from the Company's general meeting to the Board of Directors under article 5.1.2 of the Company’s articles of association. The subscription price in the Directed Issue has been set at DKK 7.98 per share (the “Subscription Price”), through an accelerated bookbuilding procedure carried out by Sedermera Corporate Finance AB (“Sedermera”). Furthermore, Curasight has entered into an loan agreement with Fenja Capital II A/S (“Fenja Capital”, the “Lender”) regarding a loan facility, conditional upon an authorizing being granted by the general meeting of the Company to the Board of Directors to issue the relevant convertible loan instrument to the Lender (the “Loan Facility”, together with the Directed Issue, the “Financing”). The Financing intends to support the clinical development of uTRACE® and uTREAT® and strengthen Curasight's financial position.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS) hereby announces its intention to carry out a directed issue of shares of a minimum of approximately DKK 15 million through an accelerated book-building procedure (the “Directed Issue”). In connection with the contemplated Directed Issue, Curasight intends to enter into an agreement with Fenja Capital II A/S (“Fenja Capital”, the “Lender”) regarding a new loan facility, which shall be conditional upon an authorization being granted by the extraordinary general meeting of the Company to the Board of Directors to issue the relevant convertible loan instrument to the Lender (the “Loan Facility”, together with the Directed Issue, the “Financing”). The Financing intends to support the clinical development of uTRACE® and uTREAT® and strengthen Curasight's financial position.

The shares will be offered exclusively to qualified investors by way of an accelerated bookbuilding process. The Directed Share Issue will be initiated immediately after publication of this announcement and may be terminated at short notice. The Company has appointed Sedermera Corporate Finance (“Sedermera”) as sole global coordinator and sole bookrunner.

Copenhagen, Denmark, 28 November 2025 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CMO professor Andreas Kjær will present the Q3 2025 Interim report and the company’s latest progress and strategy at HC Andersen Capital.

Copenhagen, Denmark, 27 November 2025 - Curasight A/S ("Curasight" or "the Company" - TICKER: CURAS) hereby publishes the interim report Q3 2025. The interim report is available as an attached file to this release and on the Company's website. Below is a summary of the report.

· Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT®
· Site given green light by European Medicines Agency (EMA) and is now open for patient enrollment – first patient dosing expected Q4 2025
· Both arms of Curasight’s theranostic approach investigating better treatment (uTREAT®) and diagnosis (uTRACE®) of certain cancers are now in clinical development

Copenhagen, 26 November 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS), a clinical stage radiopharmaceuticals company, today announced its phase 1 trial investigating uTREAT® in aggressive brain cancer is now open for patient enrollment.

Copenhagen, Denmark, 13 November 2025 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff will present the company’s latest progress and strategy at Dansk Aktionærforening InvestorDagen in Copenhagen on Monday, 17th November 2025.

· Part 1 of the trial is completed  
· Part 2 recruitment well underway; completion expected in the first half of 2026
· The Phase 2 study in prostate cancer is part of the agreement between Curium Inc. and Curasight signed in May 2023

Copenhagen, Denmark, 29 October 2025 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) announces today strong momentum in part 2 of the Phase 2 Study investigating the company’s diagnostic platform uTRACE® in prostate cancer. All nine sites across Germany, Sweden and Denmark are now fully activated and recruiting patients following the completion of part 1 of the study earlier in 2025.

· Issuance of new patent related to uTRACE® will broaden protection
· Patent coverage has been extended by 751 days and now expires 2035
· Strengthened patent protection significantly enhances the potential financial value of uTRACE®

Copenhagen, Denmark, 01 October 2025 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) announces today the issuance of US patent 12,409,240 B2 which expands the protection of the company’s uPAR diagnostic platform, uTRACE. The patent term has also been extended by 751 days (more than 2 years) so that it now expires in 2035.  This significantly extends the patent protection for uTRACE, enhancing the platform’s potential value across current and future cancer programs.

Copenhagen, Denmark, 3 September 2025 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transaction made in Curasight made by managerial employee. 

The Company’s managerial employee have given Curasight power of attorney on her behalf to publish sales of Curasight shares as managerial employee conducted 1 September 2025.

Copenhagen, Denmark, 28 August 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the half-year report 2025. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.